How do I set a price alert for HLTRF?

To set a HLTRF price alert on Stock Alarm Pro, navigate to the HLTRF quote page, select "Set Alert," choose your trigger type (price target, % move, RSI level, MACD, or volume breakout), and set your delivery channel. Stock Alarm Pro supports instant push notifications, SMS, and automated phone call alerts.

Can I get phone call alerts for HLTRF?

Yes. Stock Alarm Pro provides real-time automated phone call alerts for HLTRF. Phone call alerts ensure you are immediately awakened or interrupted during critical volatility events, overnight earnings moves, or strict stop-loss levels when silent push notifications might be overlooked.

What types of alerts can I set for HLTRF?

Stock Alarm Pro supports over 125 trigger types for HLTRF: price target alerts (above/below target), intraday percentage moves, RSI overbought/oversold levels, 50-day and 200-day moving average crossovers (golden cross / death cross), relative volume (RVOL) spikes, confirmed earnings date releases, and SEC Form-4 insider transaction filings.

How quickly will I be notified about HLTRF price changes?

HLTRF alerts are evaluated continuously in real-time against live market telemetry. Notifications are dispatched within sub-second latency via push notifications, SMS, or phone calls as soon as your trigger condition is met across regular, pre-market, and after-hours trading sessions.

Is Stock Alarm Pro free to use for HLTRF alerts?

Yes, Stock Alarm Pro offers a free tier that includes 3 active price alerts for HLTRF and other stocks. Full Pro membership is $20/month or $168/year with a 7-day free trial, unlocking unlimited alerts, phone call delivery, SMS, all 125+ technical indicators, institutional screeners, and real-time market telemetry across web, iOS, and Android.

HLTRF Company Intelligence - Business Model, Drivers & Risks

Demo Sign up Log In

HLS Therapeutics Inc.(HLTRF)

OTCMARKETClosing price · checked 5:54 PM ESTAbout this dataData status

$3.20▲0.15 (4.92%)Earnings in 6d

Extended:$3.20+0.00 (+0.00%)

WatchlistChart Studio

Explore More

HLTRF Financial Metrics

Explore 130+ historical metrics & ratios

Stock Comparison

Compare equities side by side

52-Week Highs Breakout

Stocks breaking to new annual highs

52-Week Lows Oversold

S&P 500 oversold value screener

Trending Momentum

Relative strength momentum leaders

Earnings Calendar

Upcoming earnings dates & reports

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.

HLS Therapeutics is a Canadian specialty pharmaceutical company focused on acquiring and commercializing late-stage development and commercial products in North America. The company operates a portfolio of branded specialty pharmaceuticals primarily in cardiovascular and central nervous system therapeutic areas, with key products including Clozaril (clozapine) for treatment-resistant schizophrenia and Vascepa (icosapent ethyl) for cardiovascular risk reduction. The stock trades at a micro-cap valuation reflecting revenue contraction and negative operating margins despite high gross margins typical of specialty pharma.

HealthcareSpecialty Pharmaceutical Commercializationhigh - The business model exhibits significant operating leverage potential given fixed commercialization infrastructure (sales force, regulatory compliance, distribution agreements) spread across a limited product portfolio. Revenue growth from existing products or new acquisitions would flow directly to operating income with minimal incremental variable costs beyond COGS. However, the current negative operating margin indicates the company is below breakeven scale, making it highly sensitive to revenue fluctuations. The -10.2% revenue decline is particularly damaging given high fixed cost base.

Business Overview

01Clozaril (clozapine) - treatment-resistant schizophrenia, estimated 40-50% of revenue

02Vascepa (icosapent ethyl) - cardiovascular risk reduction in high-risk patients, estimated 30-40% of revenue

03Other specialty pharmaceutical products including CNS and cardiovascular portfolio assets, estimated 10-20% of revenue

HLS operates an asset-light model acquiring commercial-stage or late-development pharmaceutical products with established clinical profiles, then commercializing them through partnerships and licensing agreements in Canadian and select North American markets. The company generates revenue through product sales to wholesalers and specialty distributors, capturing margin between acquisition costs and commercial pricing. The 84% gross margin reflects typical specialty pharma economics with low COGS, but negative operating margins indicate significant SG&A burden from commercialization infrastructure relative to current revenue scale. Pricing power is moderate, constrained by Canadian provincial formularies and US payer negotiations, with competitive positioning dependent on therapeutic differentiation rather than patent exclusivity for mature products.

What Moves the Stock

Product acquisition announcements and pipeline expansion - new commercial-stage asset additions critical for revenue diversification

Clozaril prescription volume trends and competitive dynamics in treatment-resistant schizophrenia market

Vascepa market penetration rates and formulary access decisions by Canadian provincial drug plans

Quarterly revenue performance relative to expectations given negative growth trajectory

Path to profitability milestones and operating expense management initiatives

Watch on Earnings

Product-level revenue growth/decline for Clozaril and Vascepa franchisesGross-to-net pricing adjustments and rebate/discount trendsOperating expense burn rate and adjusted EBITDA progression toward breakevenNew product launch timelines and commercial partnership agreementsCash runway and financing requirements given negative cash generation

Risk Factors

Canadian pharmaceutical pricing reform and provincial formulary restrictions limiting reimbursement rates and market access for specialty products

Generic competition and biosimilar erosion for mature products in portfolio, particularly as patent protections expire on acquired assets

Regulatory pathway changes affecting approval timelines and commercialization requirements for specialty pharmaceuticals in North American markets

Larger specialty pharma competitors with greater scale and resources competing for commercial-stage asset acquisitions, driving up acquisition multiples

Direct therapeutic competition in cardiovascular and CNS markets from both branded and generic alternatives with superior efficacy or safety profiles

Limited product differentiation for mature assets like Clozaril facing established generic competition and market saturation

Negative operating cash flow and free cash flow requiring ongoing external financing, creating dilution risk and refinancing uncertainty

Debt service obligations (0.88 D/E) consuming cash while company operates at negative margins, compressing liquidity headroom

Micro-cap market capitalization ($0.1B) limiting access to institutional capital and creating potential going-concern risks if profitability path extends

StructuralCompetitiveBalance Sheet

Macro Sensitivity

Economic Cycle

low - Specialty pharmaceutical demand for chronic conditions like treatment-resistant schizophrenia and cardiovascular disease is largely non-discretionary and insulated from economic cycles. Prescription volumes are driven by clinical need and physician treatment protocols rather than consumer spending patterns. However, the company faces indirect sensitivity through healthcare budget pressures during recessions, potentially affecting provincial formulary decisions and reimbursement rates in Canada.

Interest Rates

Rising interest rates create moderate headwinds through multiple channels: (1) higher financing costs on the company's debt (0.88 D/E ratio) directly pressure already-negative margins, (2) increased discount rates compress valuation multiples for unprofitable growth companies, making equity financing more dilutive, and (3) higher rates may reduce M&A activity and product acquisition opportunities as financing becomes more expensive. The current rate environment (March 2026) affects refinancing risk and capital availability for future product acquisitions.

Credit

Moderate credit sensitivity given the company's negative cash flow profile and reliance on external financing for operations and potential acquisitions. Tightening credit conditions would constrain access to debt financing for product acquisitions or working capital, potentially forcing dilutive equity raises. The 1.17 current ratio provides minimal liquidity buffer. Healthcare credit markets and specialty pharma lending appetite directly impact the company's ability to execute its acquisition-driven growth strategy.

Live Conditions

Russell 2000 FuturesDow Jones FuturesS&P 500 Futures

Profile

value - The stock attracts deep-value and special situations investors focused on turnaround potential, given the combination of high gross margins (84%), negative operating performance, and micro-cap valuation (1.9x P/S, 1.7x P/B). The 15.5% one-year return despite operational challenges suggests speculative interest in restructuring or M&A scenarios. Not suitable for income investors (no dividend) or growth investors (negative revenue growth). The improving net income growth (28.6% YoY) from deeply negative levels may attract distressed/turnaround specialists.

high - Micro-cap specialty pharma stocks exhibit elevated volatility driven by binary events (product approvals, acquisition announcements, financing transactions), thin trading liquidity, and operational uncertainty. The negative operating margins and cash burn create existential risk premium. Recent performance shows significant drawdowns (-11.5% over 6 months) followed by recovery, consistent with high-beta characteristics typical of sub-$200M market cap healthcare companies.

Key Metrics to Watch

Quarterly product-level revenue trends for Clozaril and Vascepa to assess portfolio stability

Adjusted EBITDA margin progression and timeline to breakeven profitability

Cash burn rate and liquidity position relative to debt maturities

New product acquisition announcements and pipeline expansion activity

Canadian provincial drug plan formulary decisions affecting reimbursement coverage

Prescription volume data from third-party sources (IQVIA, Symphony Health) for key therapeutic categories

Explore More

S&P 500 Sector Leaderboards

Fundamental Metric Rankings

Business Overview

Risk Factors

Macro Sensitivity

Profile